Patents by Inventor Namir Shaabani

Namir Shaabani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEASE INHIBITORS AS ANTIVIRALS
    Publication number: 20230322668
    Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 12, 2023
    Applicant: ACEA Therapeutics, Inc.
    Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin
  • Protease inhibitors as antivirals
    Patent number: 11753373
    Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: September 12, 2023
    Assignee: ACEA Therapeutics, Inc.
    Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin
  • Pulmonary Administration of ACE2 Polypeptides
    Publication number: 20230158125
    Abstract: The present disclosure provides methods for treating a subject having a coronavirus infection by administering a composition that includes a sACE2 polypeptide to the lungs of a subject infected with a coronavirus. The sACE2 polypeptide includes the extracellular portion of the human ACE2 polypeptide and acts as a decoy, binding the spike (S) protein of coronavirus and thereby preventing the interaction of the S protein with membrane-associated ACE2 expressed on pulmonary cells, thus disrupting the infection process. The sACE2 polypeptide is derived from human ACE2, preventing potential immune reactions of the subject to the therapeutic polypeptide. The sACE2 polypeptide is administered locally to the site of the pathology, avoiding potential adverse effects of systemic delivery.
    Type: Application
    Filed: April 20, 2021
    Publication date: May 25, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Yanliang Zhang, Heyue Zhou, Namir Shaabani, Reyna Lim, Yan Li, Chin-I Pai
  • PROTEASE INHIBITORS AS ANTIVIRALS
    Publication number: 20230026438
    Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 26, 2023
    Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin